Advertisement
NVS vs PFE
Which Stock Would AI Choose? Novartis (NVS) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- NVS has delivered stronger year-to-date returns than PFE, with performance exceeding broader market benchmarks in recent market activity.
- Novartis maintains a robust late-stage pipeline and has pursued targeted acquisitions, such as Myricx Bio, supporting growth in oncology and other areas.
- Pfizer continues to navigate post-pandemic revenue normalization, with recent earnings beats offset by ongoing litigation and supply adjustments.
- NVS trades at a higher valuation reflecting its growth profile, while PFE offers a lower price-to-earnings ratio amid sector headwinds.
- Analyst sentiment remains constructive for both, though NVS benefits from more consistent momentum and pipeline visibility in recent weeks.
- Relative positioning favors NVS for stability and catalysts, while PFE presents value-oriented considerations tied to its broader portfolio.
Introduction
Pharmaceutical giants Novartis and Pfizer operate in a dynamic healthcare sector shaped by innovation, regulatory developments, and evolving revenue streams. This comparison examines their stock performance, business drivers, and market positioning to assist investors and traders evaluating exposure to large-cap pharma. Those focused on relative strength, pipeline execution, and sector rotation may find the analysis particularly relevant amid shifting macroeconomic and industry conditions.
NVS Overview and Recent Performance
Novartis AG develops and commercializes innovative medicines across oncology, cardiovascular, immunology, and neuroscience. In recent market activity, NVS shares have shown resilience, posting year-to-date gains that outpaced broader indices. Positive sentiment has been supported by pipeline advancements, including biomarker successes in neuromuscular disease studies and European Commission approval for a spinal muscular atrophy treatment. The company also announced an acquisition to expand its cancer portfolio. Analyst coverage has remained largely favorable, with price targets reflecting measured optimism tied to mid-term growth prospects.
PFE Overview and Recent Performance
Pfizer Inc. focuses on vaccines, oncology, internal medicine, and rare diseases, with a diversified portfolio that includes established products alongside newer launches. Recent performance for PFE has been more subdued, with modest year-to-date returns amid broader market gains. Developments include a first-quarter earnings beat and reaffirmed full-year guidance, alongside operational adjustments such as temporary suspension of a product in one market and ongoing patent litigation. Sentiment reflects the transition from pandemic-related revenues, with attention on upcoming trial readouts and portfolio evolution.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots from hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, performance metrics, and risk profiles. Only those demonstrating suitability for prevailing market conditions earn placement in the trending section. Available bots span a wide range of win rates, profit factors, and drawdown statistics, allowing users to explore options aligned with specific objectives. Review the Trending AI Robots page for current selections and detailed statistics.
Head-to-Head Comparison
Novartis emphasizes specialty and innovative therapies with a concentrated pipeline, while Pfizer maintains broader exposure across vaccines and established franchises. Recent momentum has favored NVS through consistent outperformance and acquisition-driven expansion, contrasting with PFE’s focus on stabilization post-COVID revenue normalization. Risk factors for NVS include competitive pressures in key therapeutic areas; for PFE, litigation and supply chain considerations feature more prominently. Both face sector-wide regulatory and pricing environments, yet their market positioning differs in growth orientation versus value characteristics.
Tickeron AI Verdict
Based on observable factors including trend consistency, pipeline catalysts, and relative positioning, Tickeron’s AI systems currently indicate a probabilistic preference for NVS over PFE. Stronger recent performance metrics and supportive analyst commentary contribute to this assessment, though outcomes remain subject to evolving market and company-specific developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a Buy and PFE is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVS’s FA Score shows that 4 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).
- NVS’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVS’s TA Score shows that 7 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- NVS’s TA Score: 7 bullish, 2 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
NVS (@Pharmaceuticals: Major) experienced а +0.81% price change this week, while PFE (@Pharmaceuticals: Major) price change was -0.32% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.95%. For the same industry, the average monthly price growth was +1.76%, and the average quarterly price growth was +4.67%.
Reported Earning Dates
NVS is expected to report earnings on Oct 27, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.95% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| NVS | PFE | NVS / PFE | |
| Capitalization | 295B | 140B | 211% |
| EBITDA | 22.4B | 17.2B | 130% |
| Gain YTD | 15.830 | 3.641 | 435% |
| P/E Ratio | 23.42 | 18.73 | 125% |
| Revenue | 56.6B | 63.3B | 89% |
| Total Cash | 6.98B | N/A | - |
| Total Debt | 47B | 63.7B | 74% |
NVS | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 6 | 100 | |
SMR RATING 1..100 | 28 | 77 | |
PRICE GROWTH RATING 1..100 | 46 | 53 | |
P/E GROWTH RATING 1..100 | 23 | 46 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (3) in the Pharmaceuticals Major industry is in the same range as NVS (8). This means that PFE’s stock grew similarly to NVS’s over the last 12 months.
NVS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that NVS’s stock grew significantly faster than PFE’s over the last 12 months.
NVS's SMR Rating (28) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (77). This means that NVS’s stock grew somewhat faster than PFE’s over the last 12 months.
NVS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as PFE (53). This means that NVS’s stock grew similarly to PFE’s over the last 12 months.
NVS's P/E Growth Rating (23) in the Pharmaceuticals Major industry is in the same range as PFE (46). This means that NVS’s stock grew similarly to PFE’s over the last 12 months.
| NVS | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 57% |
| Stochastic ODDS (%) | 3 days ago 59% | 3 days ago 56% |
| Momentum ODDS (%) | 3 days ago 52% | 3 days ago 47% |
| MACD ODDS (%) | 3 days ago 40% | 3 days ago 44% |
| TrendWeek ODDS (%) | 3 days ago 53% | 3 days ago 59% |
| TrendMonth ODDS (%) | 3 days ago 50% | 3 days ago 47% |
| Advances ODDS (%) | 10 days ago 52% | 11 days ago 54% |
| Declines ODDS (%) | 13 days ago 46% | 7 days ago 58% |
| BollingerBands ODDS (%) | 3 days ago 59% | 3 days ago 57% |
| Aroon ODDS (%) | 3 days ago 48% | 3 days ago 60% |
Advertisement
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.16% | ||
| BMY - PFE | 61% Loosely correlated | +0.94% | ||
| MRK - PFE | 55% Loosely correlated | +0.45% | ||
| AMGN - PFE | 53% Loosely correlated | +1.22% | ||
| NVS - PFE | 51% Loosely correlated | -0.72% | ||
| BIIB - PFE | 51% Loosely correlated | +0.78% | ||
More | ||||